Cell-Permeating α -Ketoglutarate Derivatives Alleviate Pseudohypoxia in Succinate Dehydrogenase-Deficient Cells
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Succinate dehydrogenase (SDH) and fumarate hydratase (FH) are components of the tricarboxylic acid (TCA) cycle and tumor suppressors. Loss of SDH or FH induces pseudohypoxia, a major tumor-supporting event, which is the activation of hypoxia-inducible factor (HIF) under normoxia. In SDH- or FH-deficient cells, HIF activation is due to HIF1alpha stabilization by succinate or fumarate, respectively, either of which, when in excess, inhibits HIFalpha prolyl hydroxylase (PHD). To reactivate PHD, we focused on its substrate, alpha-ketoglutarate. We designed and synthesized cell-permeating alpha-ketoglutarate derivatives, which build up rapidly and preferentially in cells with a dysfunctional TCA cycle. This study shows that succinate- or fumarate-mediated inhibition of PHD is competitive and is reversed by pharmacologically elevating intracellular alpha-ketoglutarate. Introduction of alpha-ketoglutarate derivatives restores normal PHD activity and HIF1alpha levels to SDH-suppressed cells, indicating new therapy possibilities for the cancers associated with TCA cycle dysfunction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Affected cells accumulate high levels of fumarate or succinate, and manifest HIFα upregulation that can be corrected by exogenous 2-oxoglutarate (MacKenzie et al., 2007), supporting a mechanistic link through competitive inhibition of the PHDs.”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as MacKenzie et al., 2007
In the citing paper
“To date, the clearest evidence that metabolites modulate HIF signaling comes from cells that are genetically defective in fumarate hydratase (FH) (Isaacs et al., 2005) or succinate hydrogenase (SDH; subunits b, c, and d) (MacKenzie et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as MacKenzie et al., 2007
In the citing paper
“Beyond VHL disease, deficiencies in mitochondrial Krebs cycle enzymes, including succinate dehydrogenase and fumarate hydratase, promote accumulation of metabolites that inhibit PHDs, consequently facilitating HIF-α accumulation [228,229].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [228]
In the citing paper
“In fact, the latter, at least in the context of SDH loss, can be reversed by the addition of a membrane-permeable form of α-ketoglutarate (MacKenzie et al., 2007).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as MacKenzie et al., 2007
Citations
Cites
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108
Oxygen sensing by HIF hydroxylases
Schofield, C. J., & Ratcliffe, P. J. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1366 · Cited by 2,068 · cited 2×
“PHDs hydroxylate proline residues on the oxygen-dependent degradation (ODD) domain of HIF , generating docking sites for pVHL—part of an E3 ubiquitin ligase complex that targets HIF for degradation (21, 22).”
BackgroundTIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019 · cited 1×
“from the rate for converting [5-(3)H]glucose to (3)H2O, as previously described (3), without a glucose starvation step.”
MethodSelf-citationHIF-1 and tumor progression: pathophysiology and therapeutics
Semenza, G. L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02317-1 · Cited by 1,060 · cited 1×
“Under normal oxygenation conditions (normoxia), hypoxiainducible factor alpha (HIF ) proteins (HIF1 and/or HIF2 ), which are the formation-limiting units of the HIF transcription factor heteromer, are constantly both synthesized and degraded, a process that maintains them in high availability but at a very low steady…”
BackgroundIsaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.017 · Cited by 958 · cited 1×
“Moreover, it was suggested that, in vitro, fumarate is a better inhibitor of PHD than succinate ( 13 ).”
BackgroundRole of VHL Gene Mutation in Human Cancer
Kim, W. Y., & Kaelin, W. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.061 · Cited by 943 · cited 1×
“Pseudohypoxia is probably a major cause of tumors associated with VHL mutations (15).”
BackgroundArchitecture of succinate dehydrogenase and reactive oxygen species generation
Yankovskaya, V., Horsefield, R., Törnroth, S., Luna-Chavez, C., Miyoshi, H., Léger, C., Byrne, B., Cecchini, G., & Iwata, S. (2003) · Science · doi:10.1126/science.1079605 · Cited by 927 · cited 1×
“The first suggested that reactive oxygen species (ROS) from an impaired complex II of the electron transport chain (18, 30) potentially inhibit PHDs (7).”
BackgroundPollard, P. J., Brière, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi227 · Cited by 865 · cited 1×
“Pseudohypoxia was also shown recently in tumor cells with mutations in fumarate hydratase (FH) or in any of three of the four subunits of succinate dehydrogenase (SDH), SDHB, SDHC, or SDHD (5, 8, 9, 19, 20 , 28).”
BackgroundCharacterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor
Hirsilä, M., Koivunen, P., Günzler, V., Kivirikko, K. I., & Myllyharju, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304982200 · Cited by 794 · cited 1×
“Although PHDs depend on oxygen for activity, their affinity for oxygen is low (Km 230 to 250 M), making them good oxygen sensors (11).”
BackgroundSuccinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer
King, A., Selak, M. A., & Gottlieb, E. (2006) · Oncogene · doi:10.1038/sj.onc.1209594 · Cited by 672 · cited 2×
“This possibility has far-reaching consequences, since pseudohypoxia due to mTor-mediated increased translation of HIF1 has been associated with several other tumors (16).”
BackgroundSelf-citation
Cited by
Items 101–200 of 360
Makowski, L., Noland, R. C., Koves, T. R., Xing, W., Ilkayeva, O. R., Muehlbauer, M. J., Stevens, R. D., & Muoio, D. M. (2009) · The FASEB Journal · doi:10.1096/fj.08-119420 · Cited by 113
“An intriguing candidate for such signal is -ketoglutarate, a critical metabolic intermediate that also plays a role in stress response via its regulation of the hypoxia-inducible factors (HIF) 1 and 2 (33, 34).”
BackgroundSousa Fialho, M. D. L., Abd Jamil, A. H., Stannard, G. A., & Heather, L. C. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.09.024 · Cited by 112
Elevated expression of glutaminase confers glucose utilization via glutaminolysis in prostate cancer
Pan, T., Gao, L., Wu, G., Shen, G., Xie, S., Wen, H., Yang, J., Zhou, Y., Tu, Z., & Qian, W.-H. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.11.105 · Cited by 121
“TXNIP has pleiotropic roles as a tumor suppressor, such as controlling redox status via binding and inhibition of thioredoxin, enhancing the stability of p27Kip1 and destabilizing hypoxia inducible factor 1a (HIF1a) [20,21].”
BackgroundO'Flaherty, L., Adam, J., Heather, L. C., Zhdanov, A. V., Chung, Y.-L., Miranda, M. X., Croft, J., Olpin, S., Clarke, K., Pugh, C. W., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq305 · Cited by 109
Retinopathy of prematurity: A review of pathophysiology and signaling pathways
Fevereiro‐Martins, M., Marques‐Neves, C., Guimarães, H., & Bicho, M. (2022) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2022.11.007 · Cited by 126
Illsley, N. P., Caniggia, I., & Zamudio, S. (2010) · The International Journal of Developmental Biology · doi:10.1387/ijdb.082798ni · Cited by 107
“Thus, under hypoxic conditions, increased HIF-1 results in the suppression of SDHB expression, leading to increased succinate concentrations which, in turn, stabilize the increased level of HIF-1 (MacKenzie et al., 2007; Selak et al., 2005).”
BackgroundSalamanca-Cardona, L., Shah, H., Poot, A. J., Correa, F. M., Di Gialleonardo, V., Lui, H., Miloushev, V. Z., Granlund, K. L., Tee, S. S., Cross, J. R., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.10.001 · Cited by 106
“10 Cell Metabolism 26, 1–12, November 7, 2017 ally, the transport of a-KG is likely to be limiting in many cell systems, which is whymetabolic studies of the TCA cycle historically have taken advantage of dimethyl-a-KG as a cell-permeable a-KG derivative (MacKenzie et al., 2007).”
BackgroundSalminen, A., Haapasalo, A., Kauppinen, A., Kaarniranta, K., Soininen, H. S., & Hiltunen, M. O. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.001 · Cited by 113
Mailloux, R. J., Singh, R., Brewer, G., Auger, C., Lemire, J. A., & Appanna, V. D. (2009) · Journal of Bacteriology · doi:10.1128/jb.00046-09 · Cited by 129
“In fact, the activity of HIF-1, a transcription factor known for its O2-sensing attribute, is hydroxylated with the aid of KG ( 14 , 18).”
BackgroundMitochondrial complex II, a novel target for anti-cancer agents
Kluckova, K., Bezawork-Geleta, A., Rohlena, J., Dong, L., & Neuzil, J. (2013) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.10.015 · Cited by 104
Metabolic regulation of hematopoietic stem cell commitment and erythroid differentiation
Oburoglu, L., Romano, M., Taylor, N. N., & Kinet, S. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000234 · Cited by 121
“Imanirad P, Solaimani Kartalaei P, Crisan M, et al. HIF1alpha is a regulator of hematopoietic progenitor and stem cell development in hypoxic sites of the mouse embryo.”
BackgroundInfluentialGasparre, G., Kurelac, I., Capristo, M., Iommarini, L., Ghelli, A., Ceccarelli, C., Nicoletti, G., Nanni, P., De Giovanni, C., Scotlandi, K., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1042 · Cited by 104
Applications of metabolomics in cancer research
Styczynski, M. P., & Vermeersch, K. A. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.113622 · Cited by 118
Salminen, A., Kauppinen, A., & Kaarniranta, K. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1978-z · Cited by 99
Mitochondria as targets for cancer therapy
Ralph, S. J., & Neuzil, J. (2009) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200800044 · Cited by 97
Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice
Chan, S. Y., & Rubin, L. J. (2017) · European Respiratory Review · doi:10.1183/16000617.0094-2017 · Cited by 107
“For example, α-ketoglutarate (KG) is a cofactor for prolyl hydroxylation and HIF degradation [26].”
BackgroundDefining a metabolic landscape of tumours: genome meets metabolism
Nanda, C. S., Venkateswaran, S. V., Patani, N., & Yuneva, M. O. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0663-7 · Cited by 106
“Both succinate and fumarate can allosterically inhibit α-ketoglutarate-dependent prolyl-hydroxylase (PHD) and thus stabilise hypoxia-inducible factor 1α (HIF1α), which creates pseudohypoxia.(45) The mechanistic insights of HIF activation during hypoxia will be detailed later in this review.”
BackgroundObesity and Diabetic Kidney Disease: Role of Oxidant Stress and Redox Balance
Sharma, K. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6696 · Cited by 100
The multifaceted contribution of α-ketoglutarate to tumor progression: An opportunity to exploit?
Abla, H., Sollazzo, M., Gasparre, G., Iommarini, L., & Porcelli, A. M. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.031 · Cited by 103
“As already mentioned, αKG is a hydrophilic molecule with a low propensity to permeate into cells and a strategy to increase its permeability is to conjugate the ketoacid with hydrophobic carriers [54,55].”
BackgroundInfluentialRare insights into cancer biology
Adam, J., Yang, M., Soga, T., & Pollard, P. J. (2013) · Oncogene · doi:10.1038/onc.2013.222 · Cited by 93
Modern Nuclear Imaging for Paragangliomas: Beyond SPECT
Taïeb, D., Neumann, H. P. H., Rubello, D., AL-NAHHAS, A. M., Guillet, B. A., & Hindié, E. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.098152 · Cited by 90
HIF-1α as a central mediator of cellular resistance to intracellular pathogens
Knight, M., & Stanley, S. A. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.05.005 · Cited by 93
Iron control of erythroid development by a novel aconitase-associated regulatory pathway
Bullock, G. C., Delehanty, L. L., Talbot, A.-L., Gonias, S. L., Tong, W.-H., Rouault, T. A., Dewar, B., Macdonald, J. M., Chruma, J. J., & Goldfarb, A. N. (2010) · Blood · doi:10.1182/blood-2009-10-251496 · Cited by 85
Physiological consequences of complex II inhibition for aging, disease, and the mKATP channel
Wojtovich, A. P., Smith, C. O., Haynes, C. M., Nehrke, K. W., & Brookes, P. S. (2013) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.12.007 · Cited by 83
“Succinate has been shown to act as a cytosolic signaling molecule in the hypoxia-response pathway [15–17], by acting as an”
BackgroundProlyl hydroxylases as regulators of cell metabolism
Boulahbel, H., Durán, R. V., & Gottlieb, E. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370291 · Cited by 82
Zhang, W. C., Wells, J. M., Chow, K.-H., Huang, H., Yuan, M., Saxena, T., Melnick, M. A., Politi, K. A., Asara, J. M., Costa, D. B., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0052-9 · Cited by 86
Cancer-stromal interactions: Role in cell survival, metabolism and drug sensitivity
Zhang, W., & Huang, P. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.2.14623 · Cited by 80
Zlotnik, A., Sinelnikov, I., Gruenbaum, B. F., Gruenbaum, S. E., Dubilet, M., Dubilet, E., Leibowitz, A., Ohayon, S., Regev, A., Boyko, M., et al. (2012) · Anesthesiology · doi:10.1097/aln.0b013e31823d7731 · Cited by 79
“brain parenchyma, should cause pseudohypoxia and the activation of hypoxia-inducible factor under normoxia.(31) Hy-”
BackgroundClinical implications of the oncometabolite succinate in SDHx ‐mutation carriers
Eijkelenkamp, K., Osinga, T. E., Links, T. P., & van der Horst‐Schrivers, A. N. A. (2019) · Clinical Genetics · doi:10.1111/cge.13553 · Cited by 103
“Increasing levels of intracellular α-ketoglutarate have been shown to affect the levels of HIF1α in vitro.(127) As succi-”
BackgroundTherapeutic Manipulation of the HIF Hydroxylases
Nagel, S., Talbot, N. P., Mecinović, J., Smith, T. G., Buchan, A. M., & Schofield, C. J. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2711 · Cited by 86
Kurelac, I., Iommarini, L., Vatrinet, R., Amato, L. B., De Luise, M., Leone, G., Girolimetti, G., Umesh Ganesh, N., Bridgeman, V. L., Ombrato, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08839-1 · Cited by 76
Hess, J. A., & Khasawneh, M. K. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.01.006 · Cited by 85
“Both succinate dehydrogenase and fumarate dehydrogenase possess tumor suppressing functions and loss of these functions has been observed in many VHL-associated renal tumors [16].”
BackgroundHypoxia-inducible factor (HIF) network: insights from mathematical models
Cavadas, M. A., Nguyen, L. K., & Cheong, A. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-42 · Cited by 74
“The additional complexity can be encoded by changes in the molecular microenvironment [25,28,38,40-42] and brought about by feedback loops [25,28,30,31,50].”
BackgroundMetabolism and the leukemic stem cell
Abdel-Wahab, O., & Levine, R. L. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100523 · Cited by 74
“Because -KG normally serves to activate proline hydroxylases that inactivate HIF-1, depletion of -KG results in increased levels of HIF-1 and its associated targets (MacKenzie et al., 2007).”
BackgroundSerbulea, V., Upchurch, C. M., Ahern, K. W., Bories, G. F. P., Voigt, P. E., DeWeese, D. E., Meher, A. K., Harris, T. E., & Leitinger, N. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.11.002 · Cited by 78
“A striking observation was that Mox macrophages have significantly lower levels of a-ketoglutarate (a Hif1a-repressor [57] and component of the TCA cycle), while having significantly increased levels of succinate (a Hif1a-stabilizer) [57,58], which may explain how metabolism in Mox macrophages is linked to Hif1adepend…”
BackgroundInfluentialHansen, G. E., & Gibson, G. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012403 · Cited by 81
“This reverses cell death and enhances glycolysis [118,119].”
BackgroundZhang, Z., Yan, J., & Shi, H. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.012 · Cited by 79
Mitochondrial dynamics in cancer stem cells
Sessions, D. T., & Kashatus, D. F. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03773-2 · Cited by 76
Paredes, F., Sheldon, K., Lassègue, B., Williams, H. C., Faidley, E. A., Benavides, G. A., Torres, G., Sanhueza-Olivares, F., Yeligar, S. M., Griendling, K. K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720693115 · Cited by 71
Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2
Borodovsky, A., Seltzer, M. J., & Riggins, G. J. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834d816a · Cited by 78
Mutation of SDHB is a Cause of Hypoxia-Related High-Altitude Paraganglioma
Cerecer-Gil, N. Y., Figuera, L. E., Llamas, F. J., Lara, M., Escamilla, J. G., Ramos, R., Estrada, G., Hussain, A. K., Gaal, J., Korpershoek, E., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0637 · Cited by 71
“The activation of HIF-1 by inhibition of PHDs has been termed “pseudo-hypoxia,” and the effects of succinate on this process could be reversed in vitro by the addition of α-ketoglutarate (13, 14).”
Backgrounddel Balzo, U., Signore, P. E., Walkinshaw, G., Seeley, T. W., Brenner, M. C., Wang, Q., Guo, G., Arend, M., Flippin, L. A., Chow, F. A., et al. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.265181 · Cited by 79
Novel isoenzyme of 2‐oxoglutarate dehydrogenase is identified in brain, but not in heart
Bunik, V., Kaehne, T., Degtyarev, D., Shcherbakova, T., & Reiser, G. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06632.x · Cited by 68
Spallotta, F., Cencioni, C., Atlante, S., Garella, D., Cocco, M., Mori, M., Mastrocola, R., Kuenne, C. T., Günther, S., Nanni, S., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.311300 · Cited by 74
Marden, J. H. (2013) · Molecular Ecology · doi:10.1111/mec.12534 · Cited by 74
“…hydroxylase and other dioxygenases that have succinate as a reaction product Upregulation of glycolysis, tubulogenesis and tumorogenesis Maintenance of DNA methylome stability Matsumoto et al. (2006) MacKenzie et al. (2007) Tennant & Gottlieb (2010) Rzeski et al. (2012) Alpha-ketoglutarate (syn.”
BackgroundIDH1 Mutations in Gliomas: When an Enzyme Loses Its Grip
Frezza, C., Tennant, D. A., & Gottlieb, E. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.031 · Cited by 66
“These substrates inhibit the oxygensensing enzymes hypoxia-inducible factor prolyl hydroxylases (PHDs) by competing with their cosubstrate a-ketoglutarate (MacKenzie et al., 2007).”
Backgroundα‐ketoglutarate delays age‐related fertility decline in mammals
Zhang, Z., He, C., Gao, Y., Zhang, L., Song, Y., Zhu, T., Zhu, K., Lv, D., Wang, J., Tian, X., et al. (2021) · Aging Cell · doi:10.1111/acel.13291 · Cited by 65
“Other report suggests a relatively weak transmembrane activity of α-KG but it can be increased by the use of its esters (Koivunen et al., 2007; MacKenzie et al., 2007).”
BackgroundNuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer
Zecchini, V. R., Madhu, B., Russell, R. R., Pértega‐Gomes, N., Warren, A. Y., Gaude, E., Borlido, J., Stark, R., Zecchini, H. I., Rao, R. B., et al. (2014) · The EMBO Journal · doi:10.15252/embj.201386874 · Cited by 66
“Dimethyl-2-oxoglutarate (me2OG) and R59949 both have been shown to reactivate PHD and result in inhibition of HIF1A signalling (Temes et al, 2005; MacKenzie et al, 2007).”
BackgroundMitochondrial Retrograde Signalling and Metabolic Alterations in the Tumour Microenvironment
Yang, D., & Kim, J. (2019) · Cells · doi:10.3390/cells8030275 · Cited by 71
“Succinate and fumarate accumulation resulting from mutations in SDH and FH, respectively, stabilize HIF-1α via PHD inhibition, reinforcing the Warburg effect [91,97].”
Prolyl hydroxylase domain enzymes: important regulators of cancer metabolism
Pollard, P. J., Yang, M., Su, H., Soga, T., & Kranc, K. R. (2014) · Hypoxia · doi:10.2147/hp.s47968 · Cited by 87
Cardiac macrophages and emerging roles for their metabolism after myocardial infarction
Thorp, E. B. (2023) · Journal of Clinical Investigation · doi:10.1172/jci171953 · Cited by 72
“mROS activates HIF-1α (65), and succinate further stabilizes HIF-1α by leading to the inhibition of prolyl hydroxylase domain (PHD) enzymes (66).”
BackgroundIDH Mutations in Tumorigenesis and Their Potential Role As Novel Therapeutic Targets
Krell, D., Mulholland, P. J., Frampton, A. E., Krell, J., Stebbing, J., & Bardella, C. (2013) · Future Oncology · doi:10.2217/fon.13.143 · Cited by 68
Khan, M. A., Zubair, H., Anand, S., Srivastava, S. K., Singh, S., & Singh, A. P. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.003 · Cited by 62
“Diminished SDH expression or activity promotes a pseudohypoxic phenotype in cancer cells due to the accumulation of succinate, which inactivates prolyl hydroxylase (PHD), leading to HIF1α stabilization [53].”
BackgroundMetabolite therapy guided by liquid biopsy proteomics delays retinal neurodegeneration
Wert, K. J., Velez, G., Vijayalakshmi, K., Shankar, V., Evans, L. P., Sengillo, J. D., Zare, R. N., Bassuk, A. G., Tsang, S. H., & Mahajan, V. B. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102636 · Cited by 64
“In the mouse, ɑ-KG derivatives have been delivered as a treatment for hypoxic conditions without any notations of adverse side effects [59,60].”
BackgroundFuhrmann, D. C., Wittig, I., & Brüne, B. (2018) · Redox Biology · doi:10.1016/j.redox.2018.10.007 · Cited by 65
“PHD activity was restored by adding α-ketoglutarate derivatives, which competed with the inhibiting metabolites [50].”
BackgroundCurrent management of succinate dehydrogenase–deficient gastrointestinal stromal tumors
Neppala, P., Banerjee, S., Fanta, P. T., Yerba, M., Porras, K., Burgoyne, A. M., & Sicklick, J. K. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09818-0 · Cited by 62
Mitochondria and Hypoxia: Metabolic Crosstalk in Cell-Fate Decisions
Bargiela, D., Burr, S. P., & Chinnery, P. F. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.02.002 · Cited by 60
Past, Present, and Future of Molecular and Cellular Oncology
Galluzzi, L., Vitale, I., & Kroemer, G. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00001 · Cited by 66
“…obtained not only by targeting glycolysis (Bonnet et al., 2007; Simons et al., 2007) and the HIF1 signaling pathway (Brizel and Esclamado, 2006; MacKenzie et al., 2007) but also by modulating fatty acid synthesis, which is often exacerbated in cancer cells, reflecting their intense need for…”
BackgroundInfluentialChemically induced pheochromocytomas in rats: mechanisms and relevance for human risk assessment
Greim, H. A., Hartwig, A., Reuter, U., Richter-Reichhelm, H.-B., & Thielmann, H. W. (2009) · Critical Reviews in Toxicology · doi:10.1080/10408440903190861 · Cited by 63
“The displacement of -ketoglutarate from the binding site of the substrate is decisive for product inhibition; this means that not the absolute concentration of succinate is decisive, but the succinate to -ketoglutarate ratio (MacKenzie et al., 2007).”
BackgroundEvaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer
Burke, L., Butler, C. T., Murphy, A. G., Moran, B., Gallagher, W. M., O'Sullivan, J. N., & Kennedy, B. N. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00103 · Cited by 61
“…a key citric acid cycle intermediate α -ketoglutarate has been identified as a ligand GPR99 (He et al., 2004). α-ketoglutarate is also a substrate for prolyl hydroxylases which regulate hypoxia inducible factor 1α, a key player in the reprogramming of cancer metabolism (MacKenzie et al., 2007).”
BackgroundNAD+ Metabolism in Aging and Cancer
Demarest, T. G., Babbar, M., Okur, M. N., Dan, X., Croteau, D. L., Fakouri, N. B., Mattson, M. P., & Bohr, V. A. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055905 · Cited by 57
“Corresponding increases in 2-HG inhibit αKG-dependent dioxygenases, including prolyl hydroxylase (PHD), which promotes the stabilization of HIF1α.”
BackgroundWatson, E., Yilmaz, L. S., & Walhout, A. J. M. (2015) · Annual Review of Genetics · doi:10.1146/annurev-genet-112414-055257 · Cited by 55
Citric Acid Cycle Intermediates in Cardioprotection
Czibik, G., Steeples, V., Yavari, A., & Ashrafian, H. (2014) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.114.000220 · Cited by 67
“This mechanism is supported by the finding that addition of excess 2-OG is able to out-compete fumarate, thereby reactivating prolyl hydroxylase domains and hydroxylating HIF-1α.68 The possibility that different metabolic states— signaled by varying levels of CAC intermediates—can regulate the central transcriptional…”
BackgroundInfluentialEmerging Metabolic Therapies in Pulmonary Arterial Hypertension
Harvey, L. D., & Chan, S. Y. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6040043 · Cited by 61
“The TCA cycle-derived α-ketoglutarate (α-KG) is a required cofactor for PHD, the enzyme that under normal conditions causes the proteasomal degradation of HIF [24,63].”
BackgroundDesaulniers, D. M., Vasseur, P., Jacobs, A. C., Aguila, M. C., Ertych, N., & Jacobs, M. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010969 · Cited by 60
α-Ketoglutarate abrogates the nuclear localization of HIF-1α in aluminum-exposed hepatocytes
Mailloux, R. J., Puiseux‐Dao, S., & Appanna, V. D. (2008) · Biochimie · doi:10.1016/j.biochi.2008.10.014 · Cited by 61
“Recent work has indicated that succinate promotes the stabilization of HIF-1a by interfering with PHD, a dioxygenase which initiates the degradation of HIF-1a [38].”
Backgroundα-Ketoglutarate inhibits autophagy
Baracco, E. E., Castoldi, F., Durand, S., Enot, D. P., Tadić, J., Kainz, K., Madeo, F., Chery, A., Izzo, V., Maiuri, M. C., et al. (2019) · Aging · doi:10.18632/aging.102001 · Cited by 62
“Human osteosarcoma cells were cultured in the presence of three distinct precursors of α-ketoglutarate, each of which is a plasma membrane-permeable ester that can be de-esterified by cytosolic esterases to generate α-ketoglutarate, a cell impermeable compound that remains ‘trapped’ within the cell [28].”
BackgroundMethodSuccinate Dehydrogenase Loss in Familial Paraganglioma: Biochemistry, Genetics, and Epigenetics
Her, Y. F., & Maher, L. J. (2015) · International Journal of Endocrinology · doi:10.1155/2015/296167 · Cited by 58
Hypoxia and succinate antagonize 2-deoxyglucose effects on glioblastoma
Pistollato, F., Abbadi, S., Rampazzo, E., Viola, G., Puppa, A. D., Cavallini, L., Frasson, C., Persano, L., Panchision, D. M., & Basso, G. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.08.003 · Cited by 51
Yang, X., Du, T., Wang, X., Zhang, Y., Hu, W., Du, X., Miao, L., & Han, C. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.027 · Cited by 51
“6 Measure of cellular α-ketoglutarate (α-KG) concentration Cellular α-KG concentration was measured enzymatically by modification of published method [27].”
MethodFumarate Hydratase Deficiency and Cancer: Activation of Hypoxia Signaling?
Ratcliffe, P. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.03.015 · Cited by 51
Intricate crosstalk between MYC and non‐coding RNA s regulates hallmarks of cancer
Swier, L. J. Y. M., Dzikiewicz‐Krawczyk, A., Winkle, M., van den Berg, A., & Kluiver, J. L. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12409 · Cited by 55
“IDH1 converts isocitrate to a-ketoglutarate, which is an intermediate in the TCA cycle and can inhibit glycolysis via degradation of HIF1a under normoxic condition (MacKenzie et al., 2007).”
BackgroundLong-Noncoding RNA (lncRNA) in the Regulation of Hypoxia-Inducible Factor (HIF) in Cancer
Barth, D. A., Prinz, F., Teppan, J., Jonas, K., Klec, C., & Pichler, M. (2020) · Non-Coding RNA · doi:10.3390/ncrna6030027 · Cited by 61
“Subsequently, induction of α-ketoglutarate, an electron donor of PHD in HIF-1α hydroxylation and degradation [130], and decrease of ROS production suppress HIF-1α [37].”
BackgroundAntitumor effects of 2‐oxoglutarate through inhibition of angiogenesis in a murine tumor model
Matsumoto, K., Obara, N., Ema, M., Horie, M., Naka, A., Takahashi, S., & Imagawa, S. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01249.x · Cited by 53
Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics
Pal, S., Sharma, A. K., Mathew, S. P., & Jaganathan, B. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.955476 · Cited by 56
Hou, P., Kuo, C.-Y., Cheng, C.-T., Liou, J.-P., Ann, D. K., & Chen, Q. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113865 · Cited by 46
“Instead, the steady-state HIF1a level was, consistent with previous reports [14,27], down-regulated by 50% at 60-min post-treatment (Fig.”
BackgroundResultDyczynski, M., Vesterlund, M., Björklund, A.-C., Zachariadis, V., Janssen, J., Gallart‐Ayala, H., Daskalaki, E., Wheelock, C. E., Lehtiö, J., Grandér, D., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0625-7 · Cited by 51
Spégel, P., Malmgren, S., Sharoyko, V. V., Newsholme, P., Koeck, T., & Mulder, H. (2011) · Biochemical Journal · doi:10.1042/bj20100655 · Cited by 45
Badur, M. G., & Metallo, C. M. (2017) · Metabolic Engineering · doi:10.1016/j.ymben.2017.11.013 · Cited by 49
“These loss-of-function mutations lead to increases in succinate or fumarate levels within tumors, which are thought to inhibit aKGdependent dioxygenases that impact HIF1α stabilization and other biological processes (MacKenzie et al., 2007; Selak et al., 2005; Xiao et al., 2012).”
BackgroundShrimali, N. M., Agarwal, S., Kaur, S., Bhattacharya, S., Bhattacharyya, S., Prchal, J. T., & Guchhait, P. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103672 · Cited by 47
“3c) as suggested by others [37] as well as our recent work [34].”
BackgroundResultRustin, P., & Kroemer, G. (2008) · Ernst Schering Research Foundation workshop/Ernst Schering Foundation Symposium proceedings · doi:10.1007/2789_2008_086 · Cited by 47
Succinate at the Crossroad of Metabolism and Angiogenesis: Roles of SDH, HIF1α and SUCNR1
Atallah, R., Olschewski, A., & Heinemann, Á. (2022) · Biomedicines · doi:10.3390/biomedicines10123089 · Cited by 47
T cell-based cancer immunotherapy: opportunities and challenges
Ma, K., Xu, Y., Cheng, H., Tang, K., Ma, J., & Huang, B. (2025) · 中国科学通报:英文版 · doi:10.1016/j.scib.2025.03.054 · Cited by 55
Phelan, J. J., McQuaid, K., Kenny, C., Gogan, K. M., Cox, D. J., Basdeo, S. A., O’Leary, S. M., Tazoll, S. C., Maoldomhnaigh, C. Ó., O’Sullivan, M. P., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00836 · Cited by 50
Nutrient inputs and social metabolic control of T cell fate
Bacigalupa, Z. A., Landis, M. D., & Rathmell, J. C. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.009 · Cited by 48
Fletcher, S. C., & Coleman, M. L. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190333 · Cited by 55
Spontaneous hydrolysis and spurious metabolic properties of α-ketoglutarate esters
Parker, S. J., Encarnación-Rosado, J., Hollinshead, K. E. R., Hollinshead, D. M., Ash, L. J., Rossi, J. A. K., Lin, E. Y., Sohn, A. S. W., Philips, M. R., Jones, D. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25228-9 · Cited by 49
Gerometabolites: The pseudohypoxic aging side of cancer oncometabolites
MENENDEZ MENENDEZ, J., ALARCÓN, T., & Joven, J. (2014) · Cell Cycle · doi:10.4161/cc.28079 · Cited by 40
“For example, the introduction of cell-permeating α-ketoglutarate derivatives has been shown to restore normal PHD activity, which targets HIF1α for ubiquitylation and proteasomal degradation.(96) This restores normal, low levels of HIF1α in SDH-deficient cells, thus indicating that pharmacological elevation of intrace…”
BackgroundZheng, L., Zhu, Z.-R., Sneh, T., Zhang, W.-T., Wang, Z.-Y., Wu, G., He, W., Qi, H., Wang, H., Wu, X., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165028 · Cited by 43
“…through the inhibition of the DNA demethylase TET2 oncometabolic effects, including HIF activation caused by HIF prolyl hydroxylase inhibition (21–24), hypermethylation caused by inhibition of histone and DNA demethylases (25), an antioxidant response mediated by NRF2 activation (26),…”
Renal cell carcinoma: translational aspects of metabolism and therapeutic consequences
Yang, O. C. Y., Maxwell, P. H., & Pollard, P. J. (2013) · Kidney International · doi:10.1038/ki.2013.245 · Cited by 41
Linking metabolism and epigenetic regulation in development of hepatocellular carcinoma
Puszyk, W. M., Trinh, T. L., Chapple, S. J., & Liu, C. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.94 · Cited by 38
Tanaka, T., & Nangaku, M. (2009) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08r09fm · Cited by 40
Wang, M., Flaswinkel, H., Joshi, A., Napoli, M., Masgrau‐Alsina, S., Kamper, J. M., Henne, A., Heinz, A., Bérouti, M., Schmacke, N. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50104-7 · Cited by 40
“…between LPS-stimulated WT and Pfkl S775A/S775A mBMDM were due to differential PHD activity, cells were pretreated with octyl-α - ketoglutarate (octyl-α -KG), which can be converted into α -KG in cells, overriding the inhibitory effects on PHDs by endogenous metabolites, such as succinate 33 .”
Prolyl hydroxylase domain enzymes and their role in cell signaling and cancer metabolism
Nguyen, T.-L., & Durán, R. V. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.09.026 · Cited by 45
Proline Hydroxylation Primes Protein Kinases for Autophosphorylation and Activation
Lee, S. B., Ko, A., Oh, Y. T., Shi, P., D’Angelo, F., Frangaj, B., Koller, A. A., Chen, E. I., Cardozo, T. J., Iavarone, A., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.06.021 · Cited by 41
“As the PHD enzymes require αketoglutarate as co-substrate (MacKenzie et al., 2007; Schofield and Ratcliffe, 2004), we also tested the effect of α-ketoglutarate.”
MethodTCA cycle-derived oncometabolites in cancer and the immune microenvironment
Sarkar, S., Chang, C.-I., Jean, J., & Wu, M. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01186-y · Cited by 46
Energy Restriction for Breast Cancer Prevention
Howell, A., Chapman, M., & Harvie, M. (2008) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-69297-3_11 · Cited by 38
Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma
Vícha, A., Taïeb, D., & Pacák, K. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0398 · Cited by 37
“As described in our study, both succinate and ROS contribute to the inactivation of PHD and sub- sequent stabilization of the HIF1/2a signaling pathway.”
InfluentialMolecular pathogenesis of tumorigenesis caused by succinate dehydrogenase defect
Moosavi, B., Zhu, X., Yang, W., & Yang, G. (2019) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2019.151057 · Cited by 38
Three autocrine feedback loops determine HIF1α expression in chronic hypoxia
Qutub, A. A., & Popel, A. S. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.07.004 · Cited by 43
“Fumarate affects the HIF1α pathway by competing with 2-oxoglutarate, parallel to one known mechanism of succinate’s activity [69,70].”
Background
Metadata
- Authors
- MacKenzie, E. D., Selak, M. A., Tennant, D. A., Payne, L. J., Crosby, S., Frederiksen, C. M., Watson, D. G., & Gottlieb, E.
- Affiliations
- Cancer Research UK (GB)
- Tocris Cookson Ltd, Northpoint, Fourth Way, Avonmouth, Bristol BS11 8TA, United Kingdom
- University of Strathclyde (GB)
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2007-05-01
- Volume
- 27
- Issue
- 9
- Pages
- 3282-3289
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC1899954
- OpenAlex
- W2130757625
- Cited by
- 359
- References
- 31
- Citations by year
- 2026: 14 · 2025: 16 · 2024: 8 · 2023: 16 · 2022: 10 · 2021: 30 · 2020: 23 · 2019: 19 · 2018: 18 · 2017: 16 · 2016: 22 · 2015: 18 · 2014: 23 · 2013: 23 · 2012: 16
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Molecular and Cellular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Biochemical Acid Research Studies
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- succinate dehydrogenase deficiency, fumarate hydratase deficiency, pseudohypoxia, hypoxia-inducible factor-1α, prolyl hydroxylase inhibition, cancer therapy, succinic acid, fumarate
- MeSH terms
- Cell Line, Cell Membrane Permeability, Humans, Ketoglutaric Acids, Protein Binding, Succinate Dehydrogenase, Molecular Structure, Cell Hypoxia, Ubiquitin, Proteasome Endopeptidase Complex, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.